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gabapentin and pregabalin) in 2009. All selected patients had 12 months continu-
ous enrollment in the pre- and post-index periods, and were grouped into the
duloxetine or SOC cohort based on the index agent. The first dispense date was
defined as the index date, but with no use of the study medications in the prior 90
days. Both cohorts were then matched via propensity score. The propensity score
was estimated based on a logistic regressionmodel that predicted the likelihood of
initiating duloxetine adjusting for demographics, comorbidities, prior health care
utilization and costs, and priormedication history. Healthcare costs and opioid use
(those not initiated on opioids) over the 12-month post-index period were com-
pared between cohorts. RESULTS: The matched sample included 1517 patients in
both the duloxetine and SOC group. Both cohorts had a mean age of 54 years, and
were mostly females. Over the 12-month post index period, duloxetine-treated
patients had lower total health care costs than SOC-treated patients ($16,711 vs
$18,447, p0.05). They also had lower inpatient ($3,374 vs. $5,048) and outpatient
costs ($8,427 vs. $9,581), while the pharmacy costs were higher in duloxetine-
treated patients ($4,910 vs. $3,818) (all p0.05). In addition, duloxetine-treated pa-
tients were less likely to use any opioids (52% vs 63%, p0.05). CONCLUSIONS:
Commercially-insured OA patients initiating duloxetine were associated with sig-
nificantly lower health care costs and were less likely to use opioids. These results
should be interpreted with caution due to the observational nature of the claims
database.
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COST ANALYSIS OF FEBUXOSTAT VERSUS ALLOPURINOL FOR PROPHYLAXIS OF
GOUT FLARES
Jackson T, Shah R
University of Mississippi, University, MS, USA
OBJECTIVES: To perform a cost analysis of using allopurinol or febuxostat (Uloric®)
as a first-line agent for the prophylaxis of gout.METHODS: The study was carried
out from the public payer perspective. Data was extracted from three published
Phase III clinical trials and other published data for input into a Markov model
developed using TreeAge Pro 2011©. Patient inclusion criteria were consistent with
the trials, including patients with baseline serum uric acid (sUA) concentration
greater than 9 mg/dL requiring prophylaxis therapy for gout. Direct medical costs
were assessed for patients starting either allopurinol 300mg/100mg, febuxostat 80mg,
or febuxostat 120mgperdayasfirst-line therapy. Cycle lengthof 1monthwasused for
a 5 year time horizon. The model was designed so that patients who did not achieve
therapeutic goals after 1 month of initial therapy can switch to other therapeutic
groups. Incidence of drugs achieving sUA goals  6mg/dL, costs of gout flares, and
costs of drugs themselves were included. Costs associated with adverse events were
not included in the model as adverse events were not significantly different between
therapeutic groups in published trials. All costs were converted to 2009 USD. Univar-
iate sensitivity analyses were performed on all input variables. RESULTS: Using allo-
purinol 300mg/100mg as first-line therapy showed a cost of $9,242.22 per patient
for five years. Conversely, strating febuxostat 80mg or 120mg showed higher costs
per patient at $11,616.79 and $14,499.79 over 5 years, respectively. Sensitivity anal-
yses show that the modeling results were robust. CONCLUSIONS: Over a 5 year
span of time, using allopurinol as the first-line therapy for prophylaxis of gouty
flares compared to febuxostat incur lower direct medical costs. This model, how-
ever, did not consider allopurinol dose escalation up to 900mg/day, which may
have underestimated cost savings for using allopurinol as the first-line therapy.
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CARE POPULATION
Bonafede M1, Watson C2, Gandra SR3, Princic N1, Fox KM4
1Thomson Reuters, Cambridge, MA, USA, 2Amgen, Inc., Newbury Park, CA, USA, 3Amgen, Inc.,
Thousand Oaks, CA, USA, 4Strategic Healthcare Solutions, LLC, Monkton, MD, USA
OBJECTIVES: To estimate annual tumor necrosis factor (TNF)-blocker cost per
treated psoriatic arthritis (PsA) patient for etanercept, adalimumab, and infliximab
using drug utilization from a USmanaged care population.METHODS:MarketScan
Commercial Database was used to identify PsA patients, 18-64 years old, with 1
etanercept, adalimumab, or infliximab claim between November 1, 2005 and June
30, 2009. Patientswere continuously enrolled for 1 year after the initial TNF-blocker
claim (index). Sixmonths prior to index (pre-index period) was required to identify
new (no TNF-blocker claim) or continuing (had a TNF-blocker claim) patients. Pa-
tientswere excluded if they had other TNF-blocker-indicated conditions during the
pre-index period. Mean monthly dose was calculated for the three TNF-blockers
while patients were on therapy. 2011 wholesale acquisition costs were applied to
the mean monthly dose and the Medicare Physician Fee Schedule was applied to
related TNF-blocker administrations to estimate cost per treated patient.RESULTS:
Overall, 2,242 etanercept, 674 adalimumab, and 376 infliximab PsA patients were
included. Patient characteristicswere similar across treatment groupswith amean
age (SD) of 48 (10) years and 54% male. The annual TNF-blocker cost per treated
patient for all PsApatientswas $15,790 for etanercept, $18,031 for adalimumab, and
$26,973 for infliximab. The annual TNF-blocker cost per treated patient for new PsA
patients was $14,675 for etanercept, $17,133 for adalimumab, and $23,886 for inf-
liximab. For PsA patients continuing treatment, the annual TNF-blocker cost per
treated patientwas $16,195 for etanercept, $19,575 for adalimumab, and $28,663 for
infliximab. CONCLUSIONS: Based on actual drug utilization from a US managed
care population, TNF-blocker cost per treated PsA patient on adalimumab and
infliximabwere approximately 14%and 71%higher, respectively, thanTNF-blocker
cost per treated PsA patient on etanercept; patients on etanercept had the lowest
TNF-blocker cost per treated PsA patient.
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COST MINIMIZATION OF ANTI-TNF BIOLOGICS IN THE TREATMENT OF
RHEUMATOID ARTHRITIS, AKYLOSING SPONDYLITIS AND PSORIATIC
ARTHRITIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Morais AD, Pereira ML
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OBJECTIVES: To compare treatment costs of all anti-TNFa biologics treatments in
rheumatoid arthritis (RA), akylkosing spondilitis (AS) and psoriatic arthristis (PsA)
in the Brazilian public health care system. METHODS: In Brazil, four anti-TNFa
biologics are available for the treatment of RA, AS and PsA: adalimumab, etaner-
cept, infliximab, and golimumab. Yearly treatment costs were calculated for an
average patient of 70 kgs, considering dose and dosing intervals as defined in the
label for each drug. The price for adalimumab, etanercept and infliximabwas gath-
ered from the official government website for centralized purchasing, as these
drugs are already reimbursed for the three indications. The price of golimumabwas
defined according to law, based on the mandatory government discount of 24,38%
over the official list price. RESULTS: Golimumab has the lowest treatment cost
across the biologics in all indications, at R$ 21,471.94 per patient per year. This
treatment cost does not vary across indications or across years of treatment, as it does
not include a higher initial dose. Infliximab has the second lowest treatment followed
byadalimumabeat a cost ofR$29,280.00andR$36,374.00perpatient respectively.Due
to higher dosing of infliximab for AS and PsA, the average cost per patient is R$
37,820.00 similar to the yearly cost of adalimumab. Etanercept has the highest treat-
ment cost across all indications at R$ 44,800 per patient per year, with the highest
number of vials per patient per year.CONCLUSIONS:With the lowest treatment cost,
golimumab is an important treatment option for RA, AS and PsA. Given the high
expenditure of the Brazilian government with anti-TNFs, golimumabe can decrease
government expenditure between 27%-50%. Considering the total health care expen-
diture of R$ 1.67 million with adalimumab, etanercept and infliximab in the last 12
months, golimumab has the cost saving potential of about R$ 449 million.
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BACKGROUND: Information is limited regarding the costs associated with long
bone fractures in a working age population, particularly around lost productivity.
OBJECTIVES: To estimate the direct and indirect costs associated with long bone
fractures in a working age population. METHODS: Adult patients with long bone
fractures between 1/1/2001 and 12/31/2008were identified in theMarketScan Com-
mercial and Health Productivity Management Databases. Patient costs and utiliza-
tion, includingworkplace absenteeismand short termdisability, were compared in
the 6 months before and after a fracture. Observed incremental costs (i.e., the
difference in costs before and after a fracture) were reported in mutually exclusive
fracture cohorts. Multivariate adjusted costs were calculated using GLM with frac-
ture type as dummy variables. RESULTS: A total of 208,094 patients met the study
inclusion criteria for the following fracture types: tibia shaft (n49,839), radius
(n97,585), hip (n11,585), femur (n6,788), humerus (n29,884) and multiple
fractures (n12,413). The average observed direct costs in the 6-months prior to a
long bone fracture were as follows: radius ($3,291), tibia ($4,175), multiple fractures
($5,291), humerus ($5,457), femur ($8,147) and hip ($12,923). The average incremen-
tal direct cost increase in the 6-months following a fracture ranged from $5,707 for
radius fractures to $18,965 for femur fractures; observed incremental direct medi-
cal costs were $39,041 for patients with multiple fractures. Incremental observed
absenteeism costs ranged from $886 for radius fractures to $2,478 for femur frac-
tures and $3,337 for multiple fractures while incremental short term disability
costs ranged from $1,820 for radius fractures to $4,131 for hip fractures and $6,177
for multiple fractures. Multivariate adjustment yielded substantively similar re-
sults for both direct and indirect costs outcomes. CONCLUSIONS: Long bone frac-
tures are costly, both in terms of direct medical costs and lost productivity; lost
productivity represents a significant portion of the burden of long bone fractures.
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COSTS OF TREATMENT OF PEOPLE WITH RHEUMATOID ARTHRITIS IN THE
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OBJECTIVES: Rheumatoid arthritis (RA) causes significant disability and health
care expenditures. Whilst RA disability RA is characterized, related cost data are
sparse. An RA disability model from a UK biologics register was mapped to the
General Practice Research Database (GPRD) (UK) and total health care costs
estimated. METHODS: Step 1: General linear modeling was used to predict HAQ
score from RA cases from the biologics register. Step 2: healthcare costs were
estimated from RA cases with one year’s observation selected from the GPRD. Costs
(GBP2011) included prescriptions, consultations and investigations from primary and
secondary care. Step 3: the association between healthcare costs and predicted HAQ
was explored using Generalized linear modeling (Poisson distribution & log-link) and
predicted costs were fitted to predicted disability. RESULTS: Step 1&hibar;Disability
was modeled using 6129 cases, (75% female, mean age 57 years (sd 12), mean
baseline HAQ 1.81 (0.72)). Six optimal HAQmodels included: gender, age, smoking,
BMI, prior DMARDs, joint replacements, systemic RA features, current DMARD
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and steroid treatment, ESR &/or CRP; current non-RA drugs, and co-morbidities.
R2 values ranged from 0.277 (no inflammatory marker) to 0.331 (with CRP), while
mean HAQ prediction error was 0.13 (0.27). Step 2&hibar;Costs were assessed in
8,423 GPRD cases with similar gender balance (69.8% female) but older mean 64
years). Predicted HAQ (pHAQ) scores ranged from 0.45 to 3.00, with a mean of
1.78 (0.31). Mean annual cost of care in this population was £2792 (£5633), with
46% from hospital admissions, 24% prescriptions, 20% GP consultations, 11%
outpatient attendances, and 11% investigations. Step 3&hibar;Total
costs (pCOST) were optimally predicted from EXP^(5.613(Age*0.005)
(pHAQ*1.185) (Age*pHAQ*-0.001)). pCOST has an exponential correlation to
pHAQ (R20.986; EXP^(342(pHAQ*1.188)). CONCLUSIONS: Age-adjusted pre-
dicted total health care costs for RA patients increased exponentially across the
range of estimated disability. Although higher than published estimates, exclusion
of support-service costs suggests these values may be conservative.
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HEALTH CARE SYSTEM
Morais AD1, Pereira ML1, Paloni EDMP2, Ferreira CN2, Bonachela Alves F2
1Janssen Cilag Farmaceutica, São Paulo, Brazil, 2ORIZON - Companhia Brasileira de Gestão de
Serviços, Sao Paulo, Sao Paulo, Brazil
OBJECTIVES: To estimate the treatment costs of rheumatoid arthritis, psoriasis,
Crohn’s disease and ulcerative colitis in the Brazilian private health care system.
METHODS: Treatment costs were gathered from a claims database with over four
million beneficiaries for rheumatoid arthritis (AR), psoriasis (Pso), Crohn’s disease
(CD) and ulcerative colitis (UC). Patients were identified according to CID10 codes
and observed between June 2009 and August 2011. Treatment costs included hos-
pitalization, drug, procedures, exams, equipment and other costs. RESULTS: In
total 269 patients received treatment for AR, Pso, CD and UC in the Brazilian health
care system, with an expenditure of about R$ 13 million. Over 78% of expenditure
was due to drug spending, followed by hospitalization (8%), and materials (6%).
Over R$ 8.2 million (63%) were spent with 116 CD and UC patients, resulting in an
average cost of R$70.939,84 per patient. For 144 AR patients, expenditure totaled R$
4.4 million (34% of the total spending) with an average cost per patient of
R$30.834,06. Nine patients were identified with psoriasis, with a total spending of
R$334.756 (2,57%), an average of R$ 37.195,11 per patient. On average, AR patients
were hospitalized for 17 days with a total cost of R$181.422, followed by CD and UC
patients hospitalized for 15 days on averagewith a total cost of R$ 965.507. Psoriasis
patients were hospitalized on average for 4 days, with R$ 15.953 spend on average.
CONCLUSIONS: Drug spending is the main driver behind health care spending in
AR, Pso, Cd and UC in the Brazilian private health care system. Despite the lowest
hospital stay, on average psoriasis patients spend more than RA patients in the
hospital. Psoriasis represents the lowest share of total costs due to a low number of
patients observed with this disease, indicating these patients might not have ac-
cess to treatment.
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MAPPING HEALTH CARE COSTS TO CLINICAL DISEASE ACTIVITY WHERE COST
DATA IS LACKING – A NOVEL APPROACH USING MEDICAL EXPENDITURE
PANEL SURVEY DATA WITH THE CORRONA RHEUMATOID ARTHRITIS DISEASE
REGISTRY
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OBJECTIVES: To estimate incremental health care expenditures related to changes
in disease activity scores for the Clinical Disease Activity Index (CDAI) and the
modified Health Assessment Questionnaire (mHAQ) in rheumatoid arthritis (RA)
patients.METHODS: This analysis was based on a cross-sectional sample of 19,011
RA patients from the CORRONA Registry using last visit after January 1, 2009. A
mapping algorithm regressed CDAI and mHAQ severity scores from CORRONA
onto a clinically relevant group from theMedical Expenditure Panel Survey (MEPS),
based on socio-demographics, co-morbidities, and patient specific characteristics
that are available in both datasets. This analysis used ordinary least squares re-
gression andTobitmodels. Statistically significant coefficients obtained from these
regressions were used to generate CDAI and HAQ scores for all RA patients within
MEPS. Subsequently, a generalized linear model (GLM) with logarithmic transfor-
mation of annual expenditures determined the incremental costs associated with
worsening in CDAI and mHAQ scores. Total healthcare expenditures (THCE) by
pre-determined levels of RA severity were estimated. Incremental cost-per-unit of
worsening in outcome was inferred from these models. RESULTS: Relative to low
disease activity levels, patients at moderate and high disease activity levels expe-
rienced incremental increases in THCE of $3051 (95% CI: $1274, $4828) and $6221
(95% CI: $2110, $10332) respectively. A point worsening in CDAI is associatedwith a
$601 (95% CI: $359, $843) increase in annual THCE. For each 0.1 point worsening in
mHAQ there was a $621 (95% CI: $317, $925) increase in THCE. Data for the sub-
group of patients over 65 years of age demonstrated the same trend but had greater
absolute incremental costs. CONCLUSIONS: It is feasible to map clinical severity
data onto economic panel data to predict marginal economic effects of increasing
severity in RA. Patients able to attain, and maintain, lower disease activity levels
may save the health care system substantial costs.
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OBJECTIVES: Rheumatoid arthritis (RA) is associated with poor quality of life and
higher healthcare cost. This study aimed to assess the direct medical costs of
rheumatoid arthritis (RA) and to characterize predictors of these costs.METHODS:
A total of 349 RA patients were randomly selected by stratified two-stage sampling
from the China Basic Health Insurance database in 2009. All information of patient
demographic characters, clinical and costswere collected for the analysis.We used
generalized estimating equations to examine potential predictors of the costs.
RESULTS: Among 349 RA patients (mean age  58.9 years; 67% female), The mean
length-of-staywas 19.0 days for RApatientswith basicmedical insurance for urban
employees and 15.5 days for those with basic medical insurance for urban resi-
dents. The average inpatient cost was RMB8521.5 yuan (median: 6608.7, IQR:
4223.5-10383.3) and the average drug cost accounts for 49.95% of the total cost
(mean: 4256.9; median: 3681.7, IQR: 1973.7-5295.3). The multiple linear regressions
showed that the hospital cost of Patients with basic medical insurance for urban
employees had 39.6% higher costs than those with basic medical insurance for
urban residents(p0.001). Patients from tertiary hospitals had 97.8% higher costs
than those from primary hospitals; (P  0.001) and patients from municipalities
had 46.0% higher costs than those from prefecture-level cities. (P  0.01).
CONCLUSIONS: Patients with RA is associated with high hospital costs. Costs are
now driven predominantly by the cost of drugs, primarily biologic agents. and
sociodemographic characteristics such as types of health insurance and levels of
hospitals also play an important role in determination of costs.
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OBJECTIVES: To estimate the annual cost of etanercept, adalimumab and inflix-
imab per treated RA patient using US managed care drug utilization data.
METHODS: Adult patients who used tumor necrosis factor inhibitors (TNF-inhibi-
tors), specifically etanercept, adalimumab, or infliximab, were identified in the
MarketScan Commercial database between January 1, 2005 and June 30, 2009 and
were followed for 1 year (study enddatewas June 30, 2010). The index eventwas the
first use of TNF-inhibitors following a diagnosis for RA. Patients were classified as
either initiating or continuing TNF-inhibitor treatment based on their utilization
during the 6 months prior to index (pre-index period). Patients with other condi-
tions treated with TNF-inhibitors were excluded. Mean monthly dose was com-
puted for patients on therapy; September 2011 wholesale acquisition costs were
applied to mean monthly dose and 2011 Medicare Physician Fee Schedule was
applied to related drug administrations. Costs from restarting index TNF-inhibitor
therapy after discontinuation and costs from switching to a different TNF-inhibitor
were attributed to patients’ index TNF-inhibitor therapy. RESULTS: In total, 13,850
patients met the study criteria (7,035 etanercept; 3,892 adalimumab; 2,923 inflix-
imab); 44% of patients were initiators. Patient characteristics were similar across
treatment groups (mean age50.5, SD10; 76% female). The mean annual TNF-
inhibitor cost per treated RA patient was $14,892 for etanercept, $18,381 for adali-
mumab, and $23,265 for infliximab. For initiators, mean annual TNF-inhibitor cost
per treated RA patient was $14,149 for etanercept, $17,124 for adalimumab, and
$19,999 for infliximab; among patients continuing therapy, mean annual costs
were $15,423 for etanercept, $19,845 for adalimumab, and $25,232 for infliximab.
CONCLUSIONS: Etanercept had the lowest mean annual TNF-inhibitor cost per
treated RA patient when using actual drug utilization from a US managed care
population. The mean annual TNF-inhibitor costs per treated RA patient on adali-
mumab and infliximab were approximately 23% and 56% higher than etanercept,
respectively.
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COST AND PATTERN OF MOTORCYCLE ACCIDENTS AT A TERTIARY CARE
HOSPITAL IN SINDH
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OBJECTIVES: Road Traffic Injuries are considered as one of the leading causes of
mortality andmorbidity all over theworld and it is estimated that every day around
3000 people are killed in traffic injuries. Injuries caused by motorcycle accidents
constitute a major preventable burden in developing countries and contribute sig-
nificantly to the overall traffic injuries. The consequences include acute medical,
long-term medical, short-term work loss, long-term disability and lost quality of
life. This study aims to determine the direct cost for treatment incurred due to
Motorcycle incidents at a public tertiary care hospital.METHODS: Thiswas a cross-
sectional observational study. The data was reviewed from March to June 2009
during August 2009. All motorbike accident victims presented to emergency de-
partment were included in the study. Demographic, Injury related and cost data
was collected from victims or their attendants by using structured pre-tested ques-
tionnaire by experienced data collectors over phone. Chi-square test was used to
find out statistical significance at 95% confidence level. RESULTS: In total 151 pa-
tients were presented at emergency department during the period from motorcy-
cle accidents and the datawas received from 107 patients. Of these, 83%were adult
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